Drug Profile
Solimastat
Alternative Names: BB 3644Latest Information Update: 18 Feb 2004
Price :
$50
*
At a glance
- Originator British Biotech
- Class Antirheumatics; Small molecules
- Mechanism of Action Metalloprotease inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 06 Aug 2003 Discontinued - Preclinical for Inflammatory bowel disease in United Kingdom (PO)
- 06 Aug 2003 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (PO)
- 11 Oct 2001 Rights to solimastat have been returned to British Biotech by Schering-Plough